BioSpace News Archive

Professional endocrinology organization, in collaboration with leading groups in cardiometabolic disease, is hosting a virtual conference designed for the care team, by the care team

Aphex BioCleanse Systems, Inc. (OTC: SNST) (“Aphex” or “the Company”), a sanitization solutions company focused on the development and distribution of chemical-free, water-based sanitization and disinfection products, announced today that the Company has appointed CMW Media, a creative and public relations agency specializing in emerging markets, as its strategic communications firm.

Cloud DX, a leading provider of virtual care and remote patient monitoring solutions, today announced the U.S. launch of its updated Connected Health Kit, alongside a new quick-start program enabling health providers and care teams to quickly and cost-effectively expand remote patient monitoring during the COVID-19 pandemic.

Aphena Pharma Solutions announces a $21 million expansion of its Solid Dose Division in Cookeville, Tennessee, with the acquisition of a 500,000-square-foot property, purpose-built for FDA manufacturing and packaging operations.

Visuals will accompany distribution of company’s GenViro! Swift Kits globally and also be posted on the website in English, and with sub-titles in German, Russian, Spanish and French

SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone. Corin added context and his insights into the other Company news regarding the GMP production contract has been init

ALX Oncology (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, to evaluate the combination of ALX148, an investigational next generation CD47 blocker, and KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with

MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the appointment of a new President and CEO, Mr. Carsten Schroeder . The MicroVention acting President and CEO, Kazuaki Kitabatake , who has

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule

K ey cognitive endpoint s trending towards but did not reach statistical significance in early manifest population . O verall study does not meet pre-specified co- primary endpoints Results support continued development in Alzheimer’s disease and in mid-stage Huntington’s disease patients with greater cognitive deficits Company to host investor conference call today, September 22, at 8:30 a.m. EDT To access the call and webcast, please click h e re .